MEDX.SW medmix AG (SIX) earnings preview 25 Feb 2026: margins and cash flow to watch
MEDX.SW stock trades at CHF 11.40 as investors eye medmix AG’s earnings due 26 Feb 2026. The company reports after the close, and the market is focused on margins, free cash flow and dividend sustainability. Intraday volume is 64,984 versus a 50-day avg of 91,914, showing below-average activity. Key numbers to watch in the report include EPS -0.14, dividend per share 0.50 CHF, and guidance that could move the stock across the SIX market in Switzerland.
Earnings preview: MEDX.SW stock
medmix reports results on 26 Feb 2026 with investors focused on operating margin and segment performance. The company’s EPS is -0.14 and the trailing PE is -81.43, reflecting recent net losses and one-off items. Analysts will parse revenue by Dental, Drug Delivery and Surgery segments and look for margin recovery signals.
A beat on core operating profit or clearer 2026 guidance could push the price above the 50-day average of 11.44 CHF. Conversely, weaker margin commentary risks a short-term re-pricing toward the 200-day average of 10.66 CHF.
Price action and trading context for MEDX.SW stock
Medmix is trading CHF 11.40, down 0.35% intraday with a day range of 11.26–11.62 CHF. Volume at 64,984 is below the 3-month average and suggests cautious positioning ahead of earnings.
Year-to-date the stock is up 1.24%, while the one-year change is down 15.30%. Intraday underperformance versus the Industrials sector (1-day sector move +0.80%) highlights investor caution ahead of the report.
Valuation and financial metrics: MEDX.SW stock analysis
Medmix shows healthy cash generation with free cash flow per share 1.27 CHF and a price-to-sales ratio near 0.99. Book value per share is 10.55 CHF, and the stock trades at a price-to-book of 1.10. Net debt to EBITDA sits at 3.39x, and interest coverage is 2.06x, indicating leverage is a key watch item.
The company pays 0.50 CHF per share, implying a dividend yield of 4.39%, but payout sustainability depends on profit recovery and cash flow after results.
Meyka grade & forecast for MEDX.SW stock
Meyka AI rates MEDX.SW with a score out of 100: 66.91 / 100, Grade B, Suggestion HOLD. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics and analyst signals.
Meyka AI’s forecast model projects a monthly price of 8.64 CHF, a quarterly target of 12.30 CHF, and a 12-month projection of 10.86 CHF. Versus the current 11.40 CHF, the quarterly projection implies an upside of +7.90%, the 12-month outlook implies -4.77%, and the one-month view implies -24.21%. Forecasts are model-based projections and not guarantees.
Technicals, sector position and near-term catalysts
Technical indicators show neutral momentum: RSI 46.42, MACD histogram slightly negative, and Bollinger middle at 11.57 CHF. The 50-day average is 11.44 CHF and the 200-day average is 10.66 CHF, signalling short-term consolidation. ADX at 26.92 indicates a firm trend if price breaks key levels.
Catalysts include the 26 Feb earnings release, margin commentary from management, order backlog updates in Drug Delivery, and any guidance on cost savings or pricing. Watch for stock reaction to segment-level margins on the SIX market in Switzerland.
Risks and opportunites in MEDX.SW stock
Main risks: continued negative EPS, higher net debt to EBITDA and low interest coverage could pressure valuation. The company’s ROE is negative at about -1.35%, limiting upside from fundamentals alone.
Opportunities: strong free cash flow generation and a 4.39% dividend yield support income investors. Improvement in surgical and drug delivery orders would be positive, and a better-than-expected guidance could trigger a re-rating toward a CHF 13.50 upside case.
Final Thoughts
MEDX.SW stock is trading at CHF 11.40 ahead of medmix AG’s 26 Feb 2026 earnings. The report is likely to move the stock because margins, free cash flow and guidance are headline risks. Meyka AI’s forecast model projects CHF 12.30 over the next quarter (implied upside +7.90%) and CHF 10.86 at 12 months (implied downside -4.77%). Our Meyka grade (66.91/100, Grade B, HOLD) reflects mixed fundamentals: reasonable cash flow metrics but negative EPS and leverage pressure. For intraday traders, monitor reaction to segment margins and management guidance; for longer-term investors, focus on cash generation, net debt reduction and whether dividends remain supported. Use the company IR site and our Meyka AI page for live updates and post-earnings commentary before acting. Forecasts are model-based projections and not guarantees.
FAQs
When does medmix AG report earnings and what matters for MEDX.SW stock?
Medmix reports on 26 Feb 2026. Investors should watch operating margins, segment revenue, guidance and cash flow. These items will drive short-term moves in MEDX.SW stock and affect dividend sustainability.
What are the key valuation metrics to watch for MEDX.SW stock?
Focus on EPS (currently -0.14), price-to-book ~1.10, price-to-sales ~0.99, net debt/EBITDA ~3.39x, and free cash flow per share 1.27 CHF when assessing MEDX.SW stock.
How does Meyka AI view MEDX.SW stock?
Meyka AI rates MEDX.SW 66.91/100 (Grade B, HOLD). The model highlights solid cash flow but negative EPS and leverage risks. This is informational and not investment advice.
What price moves could follow the earnings release for MEDX.SW stock?
A margin beat or stronger guidance could lift MEDX.SW stock above the 50-day average toward a short-term target near 13.50 CHF. A weak report could push the stock toward the 200-day average near 10.66 CHF.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.